JG
Therapeutic Areas
Merus Pipeline
| Drug | Indication | Phase |
|---|---|---|
| Petosemtamab (MCLA-158) | 1L PD-L1+ r/m Head and Neck Squamous Cell Carcinoma (with pembrolizumab) | Phase 3 |
| BIZENGRI® (zenocutuzumab-zbco) | NRG1+ Pancreatic Adenocarcinoma & NSCLC | Approved |
| MCLA-129 | Solid Tumors | Phase 1/2 |
| MCLA-145 | Solid Tumors | Phase 1/2 |
| MCLA-122 | Solid Tumors | Phase 1 |
Leadership Team at Merus
JD
John de Kruif, Ph.D.
EVP & Chief Technology Officer
CG
Cecile Geuijen, Ph.D.
SVP & Chief Scientific Officer
EW
Ernesto Wasserman, M.D.
SVP of Clinical Development
GM
Greg Mueller
Non-Executive Director
AP
Anthony Pagano
Non-Executive Director
MJ
Martine J. van Vugt
Non-Executive Director